ReviewEmerging infectious diseases2021
Pertactin-Deficient Bordetella pertussis, Vaccine-Driven Evolution, and Reemergence of Pertussis.
Review in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Pertactin deficiency ofHuman vaccines & immunotherapeutics · 2024Pooled it
- Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda.The Lancet. Global health · 2025Trial
- Pathogenicity and vaccine protection of circulating pertactin- and filamentous hemagglutinin-deficientEmerging microbes & infections · 2026Article
- Limited protective immunity to respiratory syncytial virus and pertussis among adults and healthcare workers in South Korea: A seroepidemiologic study.Human vaccines & immunotherapeutics · 2026Article
- Review
- Allele-Skewed HLA-DR Immunopeptidomes ofVaccines · 2026Article
- Global phylogenomics of Bordetella pertussis ST2 reveals regional heterogeneity in China and lineage-specific genome evolution.BMC genomics · 2026Article
- Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin.Archives of toxicology · 2026Review
- A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.medRxiv : the preprint server for health sciences · 2026Article
- Comparing frequentist and Bayesian methods to identify drivers of pathogen strain invasion: A temporal case study of pertussis in the United States.Infectious Disease Modelling · 2026Article
- Study on the resurgence of pertussis based on a stage-structured dynamic model.Infectious Disease Modelling · 2026Article
- Development of High-Throughput Serum Bactericidal Assays forVaccines · 2026Article
- The Battle Against Pertussis: Discovery of Endogenous Human Proteins and Peptides as Toxin-Inhibitors.Toxins · 2026Review
- Released palmitic acid-mediated TLR4/NF-κB activation enhances the virulence of Bordetella pertussis MT28 lineage.Nature communications · 2026Article
- Mechanisms of natural and vaccine-induced immunity to Bordetella pertussis.PLoS pathogens · 2026Review
- Flow Cytometric Assessment of Pertactin- and Tetanus Toxoid-Specific B-Cell Kinetics After Tdap Booster Vaccination in Healthy Adults.Vaccines · 2026Article
- Article
- Structural and functional specialization of Bordetella pertussis DsbA for pertussis toxin folding.Protein science : a publication of the Protein Society · 2026Article
- EEG and seizures of pertussis encephalopathy in infants.Frontiers in pediatrics · 2026Article
- Diphtheria and pertussis outbreaks in the Americas: a scoping review of epidemiology, vaccination trends and control strategies, 2013-2024.BMJ public health · 2026Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Recent reemergence of pertussis (whooping cough) in highly vaccinated populations and rapid expansion of Bordetella pertussis strains lacking pertactin (PRN), a common acellular vaccine antigen, have raised the specter of vaccine-driven evolution and potential return of what was once the major killer of children. The discovery that most circulating B. pertussis strains in the United States have acquired new and independent disruptive mutations in PRN is compelling evidence of strong selective pressure. However, the other 4 antigens included in acellular vaccines do not appear to be selected against so rapidly. We consider 3 aspects of PRN that distinguish it from other vaccine antigens, which might, individually or collectively, explain why only this antigen is being precipitously eliminated. An understanding of the increase in PRN-deficient strains should provide useful information for the current search for new protective antigens and provide broader lessons for the design of improved subunit vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.